Regulatory Briefing · The Ledger
Medicare now covers GLP-1s for weight loss. Here's how to get the $50 price.
The Medicare GLP-1 Bridge went live July 1, 2026 — the first time Medicare has ever covered drugs prescribed solely for weight loss. Eligible enrollees pay a flat $50/month through 2027.
Live now — started July 1, 2026
Eligible Medicare Part D enrollees can get covered brand GLP-1 medications for a flat $50 per
month. The program runs through December 31, 2027. This is the first time in
Medicare's history that drugs prescribed solely for weight loss have been covered.What's actually covered
| Medication | Included? |
|---|---|
| Wegovy (semaglutide) — injections and pills | Yes, all formulations |
| Zepbound (tirzepatide) — KwikPen only | Yes |
| Zepbound single-dose vials and pens | No |
| Foundayo (orforglipron) — oral tablet | Yes |
| Compounded semaglutide / tirzepatide | No — brand only |
Who qualifies
You must have Medicare Part D coverage (standalone plan or a Medicare Advantage plan that includes drug coverage), be 18 or older, and meet one of these clinical criteria at the time you start therapy:
- BMI ≥ 30 plus a history of heart failure, uncontrolled hypertension, or chronic kidney disease, or
- BMI ≥ 27 plus prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease
The disqualifier most people miss
If you already receive a GLP-1 through Medicare Part D for a covered condition —
type 2 diabetes, cardiovascular risk reduction, or sleep apnea — you are not eligible for
the Bridge program. You keep your existing coverage instead. The Bridge is specifically for people who
had no Medicare coverage option for obesity.How to get it
- Your clinician sends a prescription for a covered GLP-1 to your pharmacy.
- That triggers a prior authorization request, which your provider completes to certify you meet the criteria and are using the drug alongside a diet-and-exercise program.
- The request goes to Humana, which CMS contracted to process Bridge approvals.
- Once approved, you pay the flat $50 copay at the pharmacy. Your authorization is valid through December 31, 2027, including refills and dose changes.
What this means if you're currently paying cash for compounded
Run this math
If you're on Medicare and paying $199–$299/month for compounded semaglutide, and you meet the Bridge
criteria, you may be able to get the FDA-approved brand drug for $50/month instead. That
is cheaper and a higher regulatory standard. Talk to your clinician about switching before you
renew another compounded month.The catches worth knowing
- The $50 copay doesn't count toward your Part D deductible or your annual out-of-pocket cap — the program sits outside Part D. (Upside: you don't have to meet a deductible to get the $50 price.)
- It expires Dec 31, 2027 unless CMS extends it or Congress changes the law. There's no clear path published beyond that date.
- Prior authorization is a real bottleneck. KFF estimates ~3.8 million beneficiaries meet the criteria; the system may strain.
- Compounded drugs are not covered. Every telehealth provider we review is cash-pay and outside this program.
Not on Medicare?
Brand direct-to-consumer pricing has fallen sharply too. Before you assume compounded is cheaper, read
compounded vs brand in 2026 — the math changed.FAQ
How much do GLP-1s cost on Medicare now?
Eligible Part D enrollees pay a flat $50 per month through the Medicare GLP-1 Bridge program, which runs from July 1, 2026 through December 31, 2027. This covers certain brand GLP-1s — Wegovy, Zepbound KwikPen, and Foundayo — not compounded versions.
Who qualifies for the Medicare GLP-1 Bridge?
You need Medicare Part D coverage and either a BMI of at least 30 with heart failure, uncontrolled hypertension, or chronic kidney disease; or a BMI of at least 27 with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. You're excluded if you already get a GLP-1 through Part D for diabetes, cardiovascular risk, or sleep apnea.
Does Medicare cover compounded semaglutide?
No. The Bridge program covers FDA-approved brand medications only. Compounded semaglutide and tirzepatide from telehealth providers remain entirely cash-pay.
Medical disclaimer: Veritide is an independent consumer-research publication, not a healthcare provider or pharmacy. This page is informational and is not medical advice. Compounded medications are not FDA-approved as finished products. Always consult a licensed clinician before starting any peptide or GLP-1 therapy.